+

WO2000045165A1 - Techniques d'identification d'agents antineoplasiques therapeutiquement efficaces avec des cellules de culture a membrane cellulaire intacte et produits correspondants - Google Patents

Techniques d'identification d'agents antineoplasiques therapeutiquement efficaces avec des cellules de culture a membrane cellulaire intacte et produits correspondants Download PDF

Info

Publication number
WO2000045165A1
WO2000045165A1 PCT/US2000/002329 US0002329W WO0045165A1 WO 2000045165 A1 WO2000045165 A1 WO 2000045165A1 US 0002329 W US0002329 W US 0002329W WO 0045165 A1 WO0045165 A1 WO 0045165A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
cells
caspase cascade
population
acid
Prior art date
Application number
PCT/US2000/002329
Other languages
English (en)
Inventor
Eckard Weber
Ben Y. Tseng
John Drewe
Sui Xiong Cai
Shailaja Kasibhatla
Original Assignee
Cytovia, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytovia, Inc. filed Critical Cytovia, Inc.
Priority to EP00907081A priority Critical patent/EP1151295A4/fr
Priority to AU28641/00A priority patent/AU2864100A/en
Publication of WO2000045165A1 publication Critical patent/WO2000045165A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Definitions

  • This invention relates to a method for identifying potential therapeutically effective antineoplastic agents.
  • the invention relates to the use of viable cultured cells having an intact cell membrane to identify compounds that directly or indirectly activate the caspase cascade. Also taught is a method for using the potentially therapeutically effective antineoplastic agents and pharmaceutical compositions for their use.
  • Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. The occurrence of cancer increases as individuals age, and the majority of cases affect adults who are middle-aged or older. In the U.S., men have a 1 in 2 lifetime risk of developing cancer, whereas for women the risk is 1 in 3. More than 11 million new cancer cases have been diagnosed since 1990 in the U.S., and more than 1 million new cancer cases are diagnosed each year. Cancer is the second leading cause of death in the U.S., exceeded only by heart disease, and since 1990 there have been approximately 5 million cancer related deaths. ⁇ ntineoplastic Agents
  • the therapeutic index is obtained by first determining the median effective dose, also termed the ED 50 , which is the dose of the drug required to produce a specified effect in 50% of a test animal population. Next, the median lethal dose, or LD 50 , is obtained by determining the dose that is lethal for 50% of an animal population. The ratio of the LD 50 to the ED 50 is the therapeutic index, or T.I. It is obviously desirable to use drugs with as high a T.I. value as possible, as these will be the safest drugs for any given purpose.
  • the T.I. values for the antineoplastic agents are typically among the lowest of any class of medicinal agents. This low T.I. is one of the greatest single problems facing the physician in treating a patient with a neoplastic disease.
  • the physician In addition to considering whether an antineoplastic agent is suited for treating the disease afflicting the patient, the physician must consider the renal (kidney) and hepatic (liver) function of the patient, as well as the general state of health of the patient, and his or her willingness to undergo arduous or painful therapy.
  • kidney renal
  • hepatic liver
  • the mechanism of action frequently involves an attack at specific phases of the cell cycle.
  • the cell cycle refers to the stages through which cells normally progress during their lifetimes. Normally, cells exist in a resting phase termed G 0 . During multiplication, cells progress to a stage in which DNA synthesis occurs, termed S. Later, cell division, or mitosis occurs, in a phase called M.
  • Antineoplastic drugs such as cytosine arabinoside, hydroxyurea, 6-mercaptopurine, and methotrexate are S phase specific, whereas antineoplastic drugs such as vincristine, vinblastine, and paclitaxel are M phase specific.
  • Prior cell based assays involved treatment of cell lines for prolonged periods with potential antineoplastic drugs.
  • the National Cancer Institute screen involves a panel of 60 cell lines that are treated for a prolonged period, for example 48-60 hours. The control cells are then counted and compared to the number of cell colonies in the treated samples. These methods, which result in dead or dying cells, have been disappointing in that they have failed to identify drugs that are effective in the presence of tumor lines with mutated p53 phenotypes.
  • a normal checkpoint in the life of cells in multicellular organisms is the process of apoptosis (see, e.g., Evan and Littlewood, Science 281:1311-1322 (1998).
  • Apoptosis is the highly conserved mechanism by which cells commit suicide. Characteristics of the process include an execution phase that includes loss of cell volume, plasma membrane blebbing and chromatin condensation, followed by packing of the cellular contents into membrane-enclosed vesicles called apoptotic bodies that are rapidly phagocytosed by neighboring cells.
  • Apoptosis differs from necrosis, which is cell death resulting from physical injury.
  • Apoptosis is one of several mechanisms that cells employ in response to the hazards raised by DNA damage.
  • apoptosis is an effective action for damaged cells that can replicate and become cancerous.
  • One major mediator of apoptosis is p53, which is a transcription factor that is normally present in low amounts because it is subject to a destruction process signaled by the Mdm-2 protein. Additionally, p53 can induce growth arrest in cells. In human cancer, p53 is often functionally inactivated so that its growth arrest activity or apoptotic activity is diminished.
  • a therapeutic treatment for cancer in which normal apoptosis is diminished, would be to enhance the apoptotic process through the administration of appropriate drugs.
  • autoimmune disease and certain degenerative diseases also involve the proliferation of abnormal cells
  • therapeutic treatment for these diseases could also involve the enhancement of the apoptotic process through the administration of appropriate drugs.
  • CED-3 is homologous to interleukin 1 ⁇ -converting enzyme, a cysteine protease, which is now called caspase- 1.
  • caspase- 1 interleukin 1 ⁇ -converting enzyme
  • the mammalian apoptosis system appears to involve a cascade of caspases, or a system that behaves like a cascade of caspases.
  • the caspase family of cysteine proteases comprises 10 different members, and more may be discovered in the future. All known caspases are synthesized as zymogens that require cleavage at an aspartyl residue prior to forming the active enzyme. Thus, caspases are capable of activating other caspases, in the manner of an amplifying cascade.
  • the caspase cascade can be involved in disease processes in two major aspects. Excessive activity of the caspase cascade can lead to excessive apoptosis and organ failure. Among the diseases that could result from this excessive activity are myocardial infarction, congestive heart failure, viral infections, rheumatoid arthritis and others. Inhibitors of the caspase cascade could thus be candidates for therapeutic intervention in such diseases. Inasmuch as methods for the discovery of enzyme inhibitors is a frequently practiced art, numerous approaches to the discovery of caspase inhibitors are available (see Villa et al. , Trends Biochem Sci. 22:388-393, (1997); Liang and Fesik, J. Mol. Biol. 274:291-302 (1991)).
  • control points are known to exist that represent points for intervention leading to activation. These control points include the CED-9 — BCL-like and CED-3 — ICE-like gene family products, which are intrinsic proteins regulating the decision of a cell to survive or die and executing part of the cell death process itself, respectively (see Schmitt et al, Biochem. Cell. Biol, 75:301-314 (1997)).
  • BCL-like proteins include BCL-xL and BAX- ⁇ , which appear to function upstream of caspase activation.
  • BCL-xL appears to prevent activation of the apoptotic protease cascade, whereas BAX- ⁇ accelerates activation of the apoptotic protease cascade.
  • BAX- ⁇ accelerates activation of the apoptotic protease cascade.
  • any assay for this purpose should be amenable to a high-throughput mode embodiment if it is to be useful for broadly based drug screening. Thus, it should be an assay that can be carried out quickly.
  • Identification of compounds that modulate caspase cascade activity may not only aid in elucidating the function of caspases, but may yield therapeutically useful compounds.
  • compounds that specifically activate specific elements of the caspase cascade should be useful in identifying essential characteristics of those elements and should aid in the design of therapeutic disease specific agents.
  • the teachings of the present invention provide a method for identifying compounds that activate the caspase cascade independent of the p53 transcription factor in viable cultured eukaryotic cells having an intact cell membrane.
  • the present invention is also directed to the use of compounds that act as activators of the caspase cascade in viable cultured eukaryotic cells having an intact cell membrane.
  • Such compounds should be useful as therapeutic agents for the treatment of caspase cascade-mediated diseases and disorders, such as neoplastic diseases and disorders, and also for the identification of the function of the caspase cascade.
  • WO98/55863 discloses a microscale method of determining the specific apoptotic activity of a cell.
  • an accessory reagent is required.
  • Such accessory reagents include reagents that allow for the lysis, solubilization or permeabilization of the cell membrane.
  • the present invention is directed to methods for identifying direct and indirect activators of the caspase cascade, therapeutic methods to use such activators, compositions for such activators, and kits comprising such activators.
  • the invention relates to a method for identifying potentially therapeutically effective antineoplastic compounds by determining the ability of test compounds to activate the caspase cascade in viable cultured eukaryotic cells having an intact cell membrane when the cells are exposed to test compounds for a predetermined period of time at a predetermined temperature, wherein a test compound is determined to have potential therapeutic efficacy if said caspase cascade activity is enhanced in response to the presence of said test compound.
  • the invention relates to a method for identifying a potentially therapeutically effective antineoplastic compound comprising determining the ability of a test compound to act as an activator of the caspase cascade in viable cultured eukaryotic cells having an intact cell membrane, wherein a test compound is determined to have potential therapeutic efficacy if said caspase cascade activity is enhanced in response to the presence of said test compound, said method comprising: obtaining viable cultured eukaryotic cells having an intact cell membrane expressing a cancer phenotype by culturing in a cell growth medium under conditions which result in growth; exposing said viable cultured cells to the test compound for a predetermined period of time at a predetermined temperature; adding a reporter compound having at least one measurable property which is responsive to the caspase cascade; measuring the caspase cascade activity of said exposed viable cultured cells by measuring said at least one measurable property; and, wherein an increase in the measured caspase cascade activity in the presence of said test compound is an indication that said test compound is a test compound
  • a permeabilization enhancer or agent may be added in combination with the test compound.
  • a reporter compound for measuring caspase activity with or without a permeabilization enhancer is added to the cell after the test compound has been incubated with the cell for a predetermined time to allow transport of the test compound across the cell membrane or interaction of the test compound with receptors on the surface of the cell membrane.
  • the predetermined period of time may be about 1 minute to less than about 24 hours, preferably about 1-24 hours, and most preferably about 3, 5, or 24 hours.
  • the predetermined temperature may be about 4 °C to about 50 °C, preferably about 37 °C.
  • the shorter predetermined period of time used in the present invention is sufficiently short to maintain an intact cell membrane in the cells being used in the assay, and makes possible the specificity of the present method for activators of the caspase cascade that are potentially therapeutically effective antineoplastic agents, rather than nonspecific cell poisons, etc.
  • the intactness of the cell membrane may be confirmed by use of propidium iodide (available from Alrich Chemical Co.) as set forth in Example 1.
  • the method of the present invention detects therapeutically important caspase cascade activator drugs, ignores non-specific cell poisons, differentiates among known antineoplastic agents such as p53 -dependent agents vs. p53 independent agents, and rapid caspase activator agents vs. other antineoplastic agents.
  • the method of the present invention offers important advantages regarding therapeutic relevance and selectivity in the discovery of new antineoplastic agents.
  • the invention also relates to methods for assaying the potency of a potentially therapeutically effective antineoplastic compound as an activator of the caspase cascade in viable cultured eukaryotic cells having an intact cell membrane.
  • the invention also relates to a method for assaying the potency of a potential therapeutically effective antineoplastic compound that functions as an activator of the caspase cascade in viable cultured eukaryotic cells having an intact cell membrane, said method comprising: obtaining a first and a second population of viable cultured eukaryotic cells having an intact cell membrane expressing a cancer phenotype by culturing said eukaryotic cells in a cell growth medium under conditions which result in growth; exposing said first population to a predetermined amount of a test compound dissolved in a solvent for a predetermined period of time at a predetermined temperature; exposing said second population to an amount of the solvent which was used to dissolve said test compound for said predetermined period of time at said predetermined temperature; adding to said test compound-exposed first population and said solvent- exposed second population a reporter compound having at least one measurable property which is responsive to the caspase cascade; measuring said at least one measurable property of said reporter compound in said test compound-exposed first population and thereby measuring
  • the invention also relates to a method for assaying the potency of a test compound to synergise with other cancer chemotherapeutic agents as an activator of the caspase cascade.
  • This method may also be employed with eukaryotic cells including, but not limited to, p53 deficient cells, Bcl-2 overexpressing family member cells, ataxia telengiectasia mutated cells, surviving overexpressing cells, bcr/abl mutated cells, pi 6 mutated cells, Brcal mutated cells, Brca2 mutated cells, multi-drug resistance cells, and DNA mismatch repair deficiency cells.
  • This aspect of the invention relates to a method for assaying the potency of a test compound to synergise with a known cancer chemotherapeutic agent by functioning as an activator of the caspase cascade, said method comprising: obtaining a first and a second population of viable cultured eukaryotic cells having an intact cell membrane expressing a cancer phenotype by culturing in a cell growth medium under conditions which result in growth; exposing said first population to a combination of a predetermined amount of a test compound and a subinducing amount of a known cancer chemotherapeutic agent for a first predetermined period of time, at a first predetermined temperature; exposing said second population to an amount of solvent which was used to dissolve the test compound and to a subinducing amount of a known cancer chemotherapeutic agent for said first predetermined period of time at said first predetermined temperature; adding a reporter compound to said exposed first population and to said exposed second population, said reporter compound having at least one measurable property which is responsive to the cas
  • the method is carried out in an automated measurement apparatus; said apparatus comprising: a controller (e.g. a computer interface control) for coordinating the operation of the apparatus; sample-containing plate comprising a plurality of wells; moving equipment, controlled by said controller for moving at least one said well to a predetermined position; liquid transfer equipment controlled by said controller for adding predetermined amounts of at least one liquid to at least one said well in a predetermined position; environmental control equipment controlled by said controller for controlling the environment (e.g. temperature or atmosphere) of said sample-containing means in a predetermined position; and measurement equipment controlled by said controller for measuring at least one attribute (e.g. fluorescence) in at least one said well in said sample-containing plate.
  • a controller e.g. a computer interface control
  • sample-containing plate comprising a plurality of wells
  • moving equipment controlled by said controller for moving at least one said well to a predetermined position
  • liquid transfer equipment controlled by said controller for adding predetermined amounts of at least one liquid to at least one said well in a predetermined position
  • the present invention includes a therapeutic method useful to modulate in vivo apoptosis or in vivo neoplastic disease, comprising administering, to an animal in need of such treatment, an effective amount of a compound, preferably with a measured ratio of at least 2, and most preferably with a measured ratio greater than a statistically significant value calculated as (Ave Control RFU + 4 x SD Contro ⁇ ) / (Ave Control RFU) for that run, or a pharmaceutically acceptable salt or prodrug of the compound, which functions as a caspase cascade activator in the method of the invention, provided that the compound is not a known apoptosis modulator and/or antineoplastic agent prior to its identification as a caspase cascade activator in the method of the invention.
  • the present invention also includes a kit for performing this therapeutic method, comprising packaging material containing the compound, or a pharmaceutically acceptable salt of the compound, and including a package label indicating that the compound, or a pharmaceutically acceptable salt or prodrug of the compound, is useful to modulate in vivo apoptosis, or one or more in vivo neoplastic diseases.
  • compositions containing therapeutically effective concentrations of the compounds formulated for oral, intravenous, local or topical application, for the treatment of neoplastic diseases and other diseases in' which caspase cascade mediated physiological responses are implicated are administered to an animal exhibiting the symptoms of one or more of these disorders.
  • the amounts are effective to ameliorate or eliminate one or more symptoms of the disorders.
  • a pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt of said compound, which functions as a caspase cascade activator according to the assay method of the invention, preferably where the ratio is at least 2, and most preferably with a measured ratio greater than a statistically significant value calculated as (Ave Control RFU + 4 x SD Control ) / (Ave Control RFU) for that run, in combination with a pharmaceutically acceptable vehicle is provided.
  • Another embodiment of the present invention is directed to a composition effective to inhibit neoplasia comprising a first compound, or a pharmaceutically acceptable salt or prodrug of said compound, which functions as a caspase cascade activator according to the assay method of the invention, preferably wherein the ratio is at least about 2, in combination with a second compound, or a pharmaceutically acceptable salt of said compound, which is a known cancer chemotherapeutic agent.
  • a composition, in which the inhibition achieved by a predetermined amount of the combination is greater than the additive effect achieved by using the first compound and the second compound individually in the amounts that each comprises in the predetermined amount of the composition is also taught.
  • Fig. 1 depicts a bar graph showing the ratio calculated for the compounds listed in Table 2 as well as the standard deviation.
  • apoptosis is a highly conserved, genetically programmed form of cellular suicide characterized by distinct morphological changes such as cytoskeletal disruption, cell shrinkage, membrane blebbing, nuclear condensation, fragmentation of DNA, and loss of mitochondrial function.
  • a caspase is a cysteine protease of the interleukin- 1 ⁇ /CED-3 family.
  • the caspase cascade is a sequential activation of at least two caspases, or the activation of caspase activity that behaves as if it involves the sequential activation of at least two caspases.
  • cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells or one in which compounds that activate the caspase cascade have therapeutic use.
  • diseases include, but are not limited to, Hodgkin's disease, non-Hodgkin's lymphomas, acute and chronic lymphocytic leukemias, multiple myeloma, neuroblastoma, breast carcinomas, ovarian carcinomas, lung carcinomas, Wilms' tumor, cervical carcinomas, testicular carcinomas, soft-tissue sarcomas, chronic lymphocytic leukemia, primary macroglobulinemia, bladder carcinomas, chronic granulocytic leukemia, primary brain carcinomas, malignant melanoma, small-cell lung carcinomas, stomach carcinomas, colon carcinomas, malignant pancreatic insulinoma, malignant carcinoid carcinomas, malignant melanomas, choriocarcinomas, mycosis fungoides, head and neck carcinomas, osteogenic sarcoma,
  • an effective amount of a compound for treating a particular disease is an amount that is sufficient to ameliorate, or in some manner reduce, the symptoms associated with the disease. Such amount may be administered as a single dosage or may be administered according to a regimen, whereby it is effective. The amount may cure the disease but, typically, is administered in order to ameliorate the disease. Typically, repeated administration is required to achieve the desired amelioration of symptoms.
  • a subinducing amount of a substance is an amount that is sufficient to produce a measurable change in caspase cascade activity when used in the method of the present invention and which produces a greater measurable change in caspase cascade activity when used in synergistic combination with a test compound in the method of the present invention.
  • alkylating agents such as busulfan, cis-platinum, mitomycin C, and carboplatin
  • antimitotic agents such as colchicine, vinblast
  • an activator of the caspase cascade is a compound, such as a drug or antibody that enhances caspase-mediated physiological responses such as cellular apoptosis.
  • the activator may act by any one or a combination of mechanisms.
  • the biological activity of the caspase cascade includes any activity induced, potentiated or influenced by the caspase cascade in vivo.
  • EC 50 refers to a dosage, concentration or amount of a particular test compound that elicits a dose-dependent response at 50% of maximal expression of a particular response that is induced, provoked or potentiated by the particular test compound.
  • pharmaceutically acceptable salts or prodrugs of the compounds include any salts, esters or derivatives that may be readily prepared by those of skill in this art using known methods for such derivatization and that produce compounds that may be administered to animals or humans without substantial toxic effects and that either are pharmaceutically active or are prodrugs.
  • hydroxyl groups can be esterified (e.g., with a C 2 . 10 alkanoyl group or succinic acid) or etherified (with a C, ⁇ alkoxy methylchloride).
  • a carboxylic acid group maybe esterified (e.g. with a C,visor 6 alcohol).
  • a prodrug is a compound that, upon in vivo administration, is metabolized or otherwise converted to the biologically, pharmaceutically or therapeutically active form of the compound.
  • the pharmaceutically active compound is modified such that the active compound will be regenerated by metabolic processes.
  • the prodrug may be designed to alter the metabolic stability or the transport characteristics of a drug, to mask side effects or toxicity, to improve the flavor of a drug or to alter other characteristics or properties of a drug.
  • treatment means any manner in which the symptoms of a condition, disorder or disease are ameliorated or otherwise beneficially altered.
  • amelioration of the symptoms of a particular disorder by administration of a particular pharmaceutical composition refers to any lessening, whether permanent or temporary, lasting or transient, that can be attributed to or associated with administration of the composition.
  • substantially pure means sufficiently homogeneous to appear free of readily detectable impurities as determined by standard methods of analysis, such as thin layer chromatography (TLC), gel electrophoresis and high performance liquid chromatography (HPLC), used by those of skill in the art to assess such purity, or sufficiently pure such that further purification would not detectably alter the physical and chemical properties, such as enzymatic and biological activities, of the substance.
  • TLC thin layer chromatography
  • HPLC high performance liquid chromatography
  • Methods for purification of the compounds to produce substantially chemically pure compounds are known to those of skill in the art.
  • a substantially chemically pure compound may be a mixture of stereoisomers. In such instances, further purification might increase the specific activity of the compound.
  • biological activity refers to the in vivo activities of a compound or physiological responses that result upon in vivo administration of a compound, composition or other mixture.
  • Biological activity thus, encompasses therapeutic effects and pharmaceutical activity of such compounds, compositions, and mixtures.
  • a fluorogenic, chromogenic or chemiluminescent substrate is a substance that produces fluorescence, light absorption within the ultraviolet, visible or infrared spectrum, or light emission under the influence of the caspase cascade.
  • Example of substrates which are useful for the screening including N-(Ac-DEVD)-N-acetyl-Rhodamine 110 (SEQ ID ⁇ O:l), N-(Ac- DEVD)-N-ethoxycarbonyl-Rhodamine 110 (SEQ ID ⁇ OJ), N-(Ac-DEVD)-N- hexyloxycarbonyl-Rhodamine 110 (SEQ ID ⁇ OJ), N-(Ac-DEVD)-N- octyloxycarbonyl-Rhodamine 110 (SEQ ID ⁇ O:l), N-(Ac-DEVD)-N- decyloxycarbonyl-Rhodamine 110 (SEQ ID ⁇ O
  • Such substrates may be prepared by a process comprising condensation of Rhodamine 110 with an acylating agent (e.g. acetic anhydride or ethylchloroformate) to give the mono-acylated Rhodamine 110 (e.g. Rhodamine 110 mono-acetate), followed by condensation with N-Ac-Asp(OBu-t)-Glu(OBu- t)-Val-Asp(OBu-t) (SEQ ID NO:l) with EDC/pyr/DMF, and removal of the t- butyl groups with trifluoroacetic acid.
  • an acylating agent e.g. acetic anhydride or ethylchloroformate
  • Other useful substrate includes Ac-DEVD-/?NA (SEQ ID NO:l), Ac- DEVD-AMC (SEQ ID NO:l), MCA-DEVDAPK(DNP)-OH (SEQ ID NO:2), Z- DEVD-AFC (SEQ ID NO:l), MCA-VDQMDGW[K-DNP]-NH 2 (SEQ ID NO:3), MCA-DEVDAR[K-DNP]-NH 2 (SEQ ID NO:4), Z-VDVAD-AFC (SEQ ID NO:5), MCA-VDVADGW[K-DNP]-NH 2 (SEQ ID NO:6), MCA- VDQVDGW[K-DNP]-NH 2 (SEQ ID NO:7), Ac-VEID-pNA (SEQ ID NO:8), Ac- VEID-AMC (SEQ ID NO:8), Z-VEID-AFC (SEQ ID NO:8) and MCA- VQVDGW[K-DNP]-NH 2 (S
  • the invention relates to a method for identifying potentially therapeutically effective antineoplastic compounds by determining the ability of test compounds to activate the caspase cascade in viable cultured eukaryotic cells having an intact cell membrane, wherein a test compound is determined to have potential therapeutic efficacy if said caspase cascade activity is enhanced in response to the presence of said test compound, the method comprising (a) obtaining viable cultured eukaryotic cells having an intact cell membrane expressing a cancer phenotype by culturing those cells in a cell growth medium under conditions which result in growth; (b) exposing the viable cultured cells to a test compound for a predetermined period of time at a predetermined temperature; (c) adding a reporter compound having at least one measurable property which is responsive to the caspase cascade; (d) measuring the caspase cascade activity of said exposed viable cultured cells by measuring said at least one measurable property of said reporter compound; and (e) wherein an increase in the measured caspase cascade activity in the presence of the test
  • the invention in another aspect, relates to a method for assaying the potency of a potentially therapeutically effective antineoplastic compound that functions as an activator of the caspase cascade in viable cultured eukaryotic cells having an intact cell membrane, comprising: (a) obtaining a first and a second population of viable cultured eukaryotic cells, each of which having an intact cell membrane expressing a cancer phenotype, by culturing said eukaryotic cells in a cell growth medium under conditions which result in growth;
  • the caspase cascade activity measured for test compounds by this method can be compared to that measured for compounds which are known to affect enzymes involved in the apoptosis cascade to generate a measure of the relative effectiveness of the test substance.
  • Compounds that can be used in comparison include known activators of enzymes involved in the apoptosis cascade.
  • known activators, either by direct or indirect mechanisms, of enzymes involved in the apoptosis cascade include but are not limited to vinblastine, etoposide (Yoon, H.J., et al, Biochim. Biophys. Acta. 1395:110-120 (1998)) and doxorubicin (Gamen, S., et al., FEBS ett.
  • a plurality of viable cultured cells are exposed separately to a plurality of test compounds, e.g. in separate wells of a microtiter plate.
  • a large number of test compounds may be screened at the same time.
  • the invention relates to a method for assaying the potency of a test compound to synergise with other cancer chemotherapeutic agents as an activator of the caspase cascade, comprising (a) obtaining a first and a second population of viable cultured eukaryotic cells, having an intact cell membrane expressing a cancer phenotype, by culturing the cell populations in a cell growth medium under conditions which result in growth; (b) exposing the first population to a combination of a predetermined amount of a test compound and a subinducing amount of a known cancer chemotherapeutic agent for a first predetermined period of time at a first predetermined temperature; (c) exposing the second population to an equal amount of solvent, which was used to dissolve the test compound, and a subinducing amount of a known cancer chemotherapeutic agent for said first predetermined period of time at said first predetermined temperature; (d) adding a reporter compound to the exposed first population and to the exposed second population, the reporter compound having at
  • Reporter compounds are preferably used as a means for measuring caspase cascade activity in the whole-cell assays of the present invention.
  • Typical reporter compounds include fluorogenic, chromogenic or chemiluminescent compounds applied to cells or tissues containing cells at a concentration of about 0.01 nanomolar to about OJ molar, or an equivalent amount of a salt or prodrug thereof. A most preferred concentration is about 10 micromolar.
  • the test compounds are preferably presented to the cells or cell lines dissolved in a solvent.
  • Preferred solvents include, DMSO, water and/or buffers.
  • a most preferred solvent is DMSO.
  • the preferred amount of DMSO is generally below 2% and most preferably 1% or below. At this concentration, DMSO functions as a solubilizer for the test compounds and not as a permeabilization agent.
  • the amount of solvent tolerated by the cells must be checked initially by measuring cell viability or caspase induction with the different amounts of solvent alone to ensure that the amount of solvent has no effect on the cellular properties being measured.
  • Suitable buffers include cellular growth media, for example Iscove's media (Life Technologies, Inc.) with or without 10% fetal bovine serum.
  • Other known cellular incubation buffers include phosphate, PIPES or HEPES buffers.
  • the cells can be derived from any organ or organ system for which it is desirable to find a potentially therapeutically effective antineoplastic compound that functions as an activator of the caspase cascade in viable cultured eukaryotic cells having an intact cell membrane.
  • Cellular genotypes for screening of test compounds include, but are not limited to, cells that are P53 negative, Bcl-2 overexpressing, Bcl-xL overexpressing, ataxia telengiectasia mutated (e.g. ATCC CRL 7201), multi-drug resistance (e.g.
  • P-glycoprotein overexpressing ATCC CRL-1977
  • DNA mismatch repair deficiency e.g., defects in hMSH2, hMSH3, hMSH6, hPMS2, or hPMSl
  • HL-60 cells ATCC CCL-240
  • SH-SY5Y cells ATCC CRL-2266
  • Jurkat cells ATCC TIB- 152
  • surviving overexpressing e.g. ATCC CCL-185
  • bcr/abl mutated eg ATCC CCL-243
  • pi 6 mutated e.g. ATCC CRL-2336)
  • Brca2 mutated e.g. ATCC CRL-1977
  • DNA mismatch repair deficiency e.g., defects in hMSH2, hMSH3, hMSH6, hPMS2, or hPMSl
  • HL-60 cells ATCC CCL-240
  • SH-SY5Y cells ATCC CRL-2266
  • Jurkat cells ATCC TIB
  • Suitable solubilizers may be used for presenting reporter compounds to cells or cell lines.
  • Preferred solubilizers include aqueous solutions of the test compounds in water-soluble form, for example as water-soluble salts. More preferably, the test compounds are dissolved in a buffer solution containing 20% sucrose (Sigma) 20 mM DTT (Sigma), 200 mM NaCl (Sigma), and 40 mM Na PIPES buffer pH 7.2 (Sigma).
  • permeabilization agents include, but are not limited to, NP-40, n-octyl-O-D-glucopyranoside, n-octyl-O-D- thioglucopyranoside, taurocholic acid, digitonin, CHAPS, lysolecithin, dimethyldecylphosphine oxide (APO-10), dimethyldodecylphosphine oxide (APO-12), N,N-bis-(3-D-gluconamidopropyl)cholamide (Big Chap), N,N-bis-(3- D-gluconamidopropyl)deoxycholamide (Big Chap, deoxy), BRIG-35, hexaethyleneglycol (C10E6), C10E8, C12E6, C12E8, C
  • the cell lines are exposed to a predetermined amount of test compounds at concentrations in the range from about 1 picomolar to about 1 millimolar, preferably about 1-10 micromolar.
  • the predetermined period of time may be about 1 minute to less than about 24 hours, preferably 1-24 hours, and most preferably 3, 5, or 24 hours.
  • the predetermined temperature may be about 4 °C to about 50 °C, preferably about 37 °C.
  • the Relative Fluorescence Unit values are used to calculate the potency of the test compounds as follows:
  • the potency of caspase cascade activation is determined by the ratio of the Net
  • Net RFU of test compound _ R Net RFU of control sample Preferred test compounds are those indicating a ratio of 2 or greater and most preferably with a measured ratio greater than a statistically significant value calculated as (Ave Control RFU + 4 x SD Control ) / (Ave Control RFU) for that run.
  • preferred compounds can also be determined by reference to Tables 1, 2, 3, and 4 which set forth exemplary compounds. Table 2 reports the average data and standard deviation for a number of compounds shown in Table 1. See also Fig. 1 which shows the standard deviation error bar. These results demonstrate that the test compounds that have a ratio around the control value have consistent values and do not lead to false positives. The results also show that compounds with ratios above about 1.5 exhibit wider variation in the numbers they generate. Thus, the assay may give false negatives unless it is run several times.
  • Table 1 indicates the results of the propidium iodide test described in Example 1 herein, wherein cells that show a propidium iodide ratio of about 1 are viable cells having an intact cell membrane. Table 1 provides evidence for the effectiveness of the present invention for the purpose of identifying potentially therapeutically effective antineoplastic agents.
  • the method of the present invention detects therapeutically important caspase activator drugs, ignores non-specific cell poisons, differentiates among known antineoplastic agents such as p53-dependent agents vs. non-p53 independent agents and rapid caspase activator agents vs. other antineoplastic agents.
  • the method offers important advantages regarding therapeutic relevance and selectivity in the discovery of new antineoplastic agents, over currently available methods.
  • Table 3 summarizes the results of a library of 800 generic compounds, using 80 compounds per plate. Potentially therapeutically effective antineoplastic agents identified in this library, having a ratio greater than about 2 are shown. Representative samples of inactive compounds, which do not have a ratio greater than about 2, are also shown.
  • Table 4 shows the results from a library of 640 natural products, tested using 80 compounds per plate. Potentially therapeutically effective antineoplastic agents identified in this library, having a ratio greater than about 2 are shown.
  • the present assay identifies the following compounds as activators of the caspase cascade having a potency ratio of greater than about 2 in viable cultured eukaryotic cells having an intact cell membrane: aklavin hydrochloride, citrinin, cytochalasin d, chloroquine, gramicidin, rotenone, cetylpyridinium chloride, staurosporine, emetine, etoposide, digitoxin, ouabain, benzethonium chloride, baclofen, bithinolate sodium, apomorphine, amphotericin B, colchicine, dehydrocholic acid, dienestrol, gentian violet, hexylresorcinol, disulfiram, gamma aminobutyric acid, furosemide, hydroxyprogesterone caproate, mechlorethamine, oxyphenbutazone, strophanthidin, tyrothricin, pimethixene, estradi
  • l-(2- ⁇ -epoxy)-deacetoxydihydrogedunin mexicanolide enol acetate, 4,4' -dimethoxydalberginone, methyl gamboginate, obtusaquinone, brazilin trimethyl ether, isorhodomyrtoxin, juglone, resistomycinolide. cucumin, dihydrocinchonidin, leodin diacetate, and 18 ⁇ -glycyrrhetic acid.
  • Effective concentrations of one or more of the caspase cascade activators or pharmaceutically acceptable salts, or prodrugs thereof are mixed with a suitable pharmaceutical carrier or vehicle.
  • methods for solubilizing compounds may be used. Such methods are known to those of skill in this art, and include, but are not limited to, using solubilizers, such as dimethylsulfoxide (DMSO), surfactants, such as polysorbate 80, dissolution in aqueous sodium bicarbonate, or use of transdermal penetration enhancers (e.g., AZONE TM).
  • the resulting mixture may be a solution, suspension, emulsion or the like.
  • the form of the resulting mixture depends upon a number of factors, including the intended mode of administration and the solubility of the compounds in the selected carrier or vehicle.
  • compositions suitable for administration of the compounds provided herein include any such carriers known to those skilled in the art to be suitable for the particular mode of administration.
  • the compounds may be formulated as the sole pharmaceutically active ingredient in the composition or may be combined with other active ingredients.
  • the active compounds can be administered by any appropriate route, for example, bucally, intransally, orally, parenterally, intravenously, intradermally, subcutaneously, or topically, in liquid, semi-liquid, or solid form formulated in a manner suitable for each route of administration.
  • Preferred modes of administration include oral, nasal and parenteral modes of administration.
  • the active compound is included in the pharmaceutically acceptable carrier in an amount sufficient to exert a therapeutically useful effect in the absence of undesirable side effects on the patient treated.
  • concentration of active compound in the drug composition will depend on absorption, inactivation and excretion rates of the active compound, the dosage schedule, and amount administered as well as other factors known to those of skill in the art.
  • a therapeutically effective dosage should produce a serum concentration of active ingredient from about about 50-100 pg/ml to 0J mg/ml.
  • the pharmaceutical composition typically should provide a dosage of from about 0.01 mg to about 10 mg of compound per kilogram of body weight per day.
  • the active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at selected intervals of time.
  • the precise dosage and duration of treatment is a function of the disease being treated and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data. It is to be noted that concentrations and dosage values may also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions.
  • the compound may be provided in a composition that protects it from the acidic environment of the stomach.
  • the composition can be formulated in an enteric coating (e.g. with hydroxypropylmethyl cellulose phthalate) that maintains its integrity in the stomach and releases the active compound in the intestine (See Remington's Pharmaceutical Sciences, Osol, A., ed., Mack Publishing Co. (1980)).
  • the composition may also be formulated in combination with an antacid or other such ingredient.
  • Oral compositions will generally include an inert diluent or an edible carrier and may be compressed into tablets or enclosed in gelatin capsules.
  • the active compound or compounds can be incorporated with excipients and used in the form of tablets, capsules or troches.
  • Pharmaceutically compatible binding agents and adjuvant materials can be included as part of the composition.
  • the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder, such as microcrystalline cellulose, gum tragacanth and gelatin; an excipient such as starch and lactose; a disintegrating agent such as, but not limited to, alginic acid and corn starch; a lubricant such as, but not limited to, magnesium stearate; a glidant, such as, but not limited to, colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; and a flavoring agent such as peppermint, methyl salicylate. or fruit flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth and gelatin
  • an excipient such as starch and lactose
  • a disintegrating agent such as, but not limited to, alginic acid and corn starch
  • a lubricant such as, but not limited to, magnesium stearate
  • the dosage unit form When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil.
  • dosage unit forms can contain various other materials that modify the physical form of the dosage unit, for example, coatings of sugar and other enteric agents.
  • the compounds can also be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like.
  • a syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
  • the active material can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as antacids, H2 blockers, and antimetabolites.
  • materials that supplement the desired action such as antacids, H2 blockers, and antimetabolites.
  • the compound may be used with other antineoplastic agents.
  • Solutions or suspensions used for parenteral, intradermal, subcutaneous, intranasal or topical application can include any of the following components: a sterile diluent, such as water for injection, saline solution, fixed oil, polyethylene glycol, glycerin, propylene glycol or other synthetic solvent; antimicrobial agents, such as benzyl alcohol and methyl parabens; antioxidants, such as ascorbic acid and sodium bisulfite; chelating agents such as ethylenediaminotetraacetic acid (EDTA); buffers, such as acetate, citrates, and phosphates; and agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • a sterile diluent such as water for injection, saline solution, fixed oil, polyethylene glycol, glycerin, propylene glycol or other synthetic solvent
  • antimicrobial agents such as benzyl alcohol and methyl parabens
  • antioxidants such as ascorbic acid and
  • suitable carriers include physiological saline or phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof.
  • PBS physiological saline or phosphate buffered saline
  • suitable carriers include physiological saline or phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof.
  • Liposomal suspensions, including tissue-targeted liposomes may also be suitable as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art. For example, lipsome formulations may be prepared as described in U.S. Pat. No. 4,522,811.
  • the active compounds may be prepared with carriers that protect the compound against rapid elimination from the body, such as time release formulations or coatings.
  • carriers include controlled release formulations, such as, but not limited to, implants and microencapsulated delivery system, and biodegradable, biocompatible polymers, such as collagen, ethylene vinyl acetate, polyanhydrides, polyglycolic acid, polyorthoesters, polylactic acid and others. Methods for preparation of such formulations are known to those skilled in the art.
  • the compounds may be formulated for local or topical application, such as for topical application to the skin and mucous membranes, such as in the nose or eye, in the form of gels, creams, and lotions.
  • the compounds may be formulated for application to the eye, or for intracisternal or intraspinal application in the form of solutions.
  • solutions particularly those intended for ophthalmic use, may be formulated as 0.01%- 10% isotonic solutions, pH about 5-7, with appropriate salts.
  • the compounds may be formulated as aerosols for topical application, such a by inhalation (see, e.g. U.S. Pat. Nos. 4,044,126, 4,414,209 and 4,364,923, which describe aerosols for delivery of a steroid useful for treating inflammatory diseases, particularly asthma).
  • the compounds may be packaged as kits containing packaging material, a compound identified by the method of the invention which is effective as an antineoplastic agent, ameliorating the symptoms of a neoplastic disorder, or activating the caspase cascade, and a packaging label that indicates that the compound or salt thereof is used as an antineoplastic agent, or for treating caspase cascade mediated disorders.
  • HL-60 cells were grown in Iscove's media (Life Technologies, Inc.) + 10% FCS (Sigma Chemical Company) in a 5% C0 2 -95% humidity incubator at 37 °C, and maintained at a cell density between 1 and 6 x 10 5 cells/ml. Cells were harvested at 600xg and resuspended at 2J x 10 6 cells/ml into Iscove's media + 1 % FCS. An aliquot of 45 ⁇ l of cells was added to at least one well of a 96- well microtiter plate containing 5 ⁇ l of 10% DMSO in Iscove media solution containing the test compound as the test solution and at least one other well that is free of the test compound as a control sample. The samples were agitated and then incubated at 37 °C for 3 hr in a 5% C0 2 -95% humidity incubator.
  • the Relative Fluorescence Unit values were used to calculate the sample readings as follows:
  • Viable cells with an integral cell membrane are those indicating a ratio of about 1 whereas non-viable cells with damaged membranes have ratios as high as 3.6.
  • HL-60 cells were maintained and harvested as described in Example 1. An aliquot of 45 ⁇ l of HL-60 cells was added to a well of a 96-well microtiter plate containing 5 ⁇ l of a 10%> DMSO in Iscove media solution containing 30 ⁇ g per ml of vinblastine sulfate. An aliquot of 45 ⁇ l of cells was added to a well of a 96-well microtiter plate containing 5 ⁇ l of a 10% DMSO in Iscove media solution without vinblastine as the control sample. The samples were mixed by agitation and then incubated at 37 °C for 3 hr in a 5% CO 2 -95% humidity incubator.
  • the Relative Fluorescence Unit values were used to calculate the sample readings as follows:
  • vinblastine is identified as an antineoplastic compound that is a caspase cascade activator in this assay.
  • the assay was run under the same conditions described in Example 2 with vinblastine being replaced by cyclophosphamide.
  • cyclophosphamide is identified as an antineoplastic compound that is not a caspase cascade activator in this assay.
  • HL-60 cells were grown and harvested as in Example 1. Aliquots of 45 ⁇ l of cells, using an 8-channel multi-pipettor (Eppendorf), were added to wells of a 96-well microtiter plate — each plate containing 5 ⁇ l of a 10% DMSO in Iscove media solution containing 30 ⁇ g per ml of a known antineoplastic, antibacterial, antimetabolite, immunosuppressive, cell poison or other compound. An aliquot of 45 ⁇ l of cells was added to a well of a 96-well microtiter plate containing 5 ⁇ l of a 10%> DMSO in Iscove media solution without a test compound as the control sample.
  • Eppendorf 8-channel multi-pipettor
  • the samples were mixed by agitation and then incubated at 37 °C for 3 hr in a 5% CO 2 -95% humidity incubator. After incubation, the samples were removed from the incubator and 50 ⁇ l of a solution containing 20 ⁇ M of N-(Ac-DEVD)-N'-ethoxycarbonyl-R110 (SEQ ID ⁇ OJ) fluorogenic substrate, 20% sucrose (Sigma), 20 mM DTT (Sigma), 200 mM ⁇ aCl (Sigma), 40 mM ⁇ a PIPES buffer pH 7.2 (Sigma), and 500 ⁇ g/ml lysolecithin was added using an 8-channel multi-pipettor (Eppendorf).
  • Eppendorf 8-channel multi-pipettor
  • the potency of caspase cascade activation was determined by the ratio of the net RFU value for each sample to that of control samples to determine the potency of caspase cascade activation as shown in Table 1 herein.
  • the assay detects therapeutically important known antineoplastic compounds which activate the caspase cascade.
  • the assay also detects compounds which activate the caspase cascade but are not known to be antineoplastic.
  • the assay does not detect non-specific cell poisons or cytotoxic compounds.
  • HL-60 cells were grown and harvested as described in Example 1. All additions were made with a 96-well liquid handling apparatus (Quadra 96. Tomtec Instruments). Aliquots of 45 ⁇ l of cells was added to wells of a 96-well microtiter plate, each well containing 5 ⁇ l of a 10%) DMSO in Iscove media solution containing 30 ⁇ g per ml of test compound. An aliquot of 45 ⁇ l of cells was added to a well of a 96-well microtiter plate containing 5 ⁇ l of a 10% DMSO in Iscove media solution without a test compound as the control sample.
  • the samples were mixed by agitation and then incubated at 37 °C for 3 hr in a 5% CO 2 -95%) humidity incubator. After incubation, the samples were removed from the incubator and 50 ⁇ l of a solution containing 20 ⁇ M of N-(Ac-DEND)- N'-ethoxycarbonyl-Rl lO (SEQ ID ⁇ OJ) fluorogenic substrate, 20% sucrose (Sigma), 20 mM DTT (Sigma), 200 mM ⁇ aCl (Sigma), 40 mM ⁇ a PIPES buffer pH 1.2 (Sigma), and 500 ⁇ g/ml lysolecithin was added. The samples were mixed by agitation and incubated for 3 hr at room temperature.
  • the following procedure was conducted in an automated measurement apparatus for automatic drug screening.
  • the apparatus is designed to initiate and measure events such as enzymatic transformations.
  • the apparatus is designed to measure a resulting attribute of the sample for a period of time, record and process the resulting data, and present the processed data on a printer, magnetic storage device, or video display.
  • HL-60 cells were grown and harvested as described in Example 1.
  • Solid tumor cells are frequently resistant to many standard chemotherapeutic agents and lack of activation of apoptosis indicates a lack of efficacy as an antineoplastic agent.
  • T47D and ZR 75-1 human breast cancer lines or PC3 prostate cancer line were maintained with appropriate media (ATCC recommended media + 10% FCS).
  • Cells were harvested and resuspended at O. ⁇ xlO 6 cells/ml in media + 10%> FCS. An aliquot of 45 ⁇ l of cells was added to each well of a 96-well microtiter plate.
  • the Relative Fluorescence Unit values were used to calculate the sample readings as follows:
  • vinblastine at 10 ⁇ M had a ratio of 2J with T47D cells, a ratio of 1.4 with ZR 75-1 cells, and a ratio of 1.3 with PC3 cells. The low ratios indicate that the compound is not effective with these resistant solid tumor cells.
  • staurosporine at 5 ⁇ M the ratio was 6.1 with T47D, 9.5 with ZR 75-1 cells, and 2.5 with PC3 cells indicating a more potent caspase activation and more efficacy in cell killing.
  • Caspase activation can also be assessed when the reporter compound is presented directly to cells without a permeabilizer for the reporter substrate.
  • T47D and ZR 75-1 human breast cancer lines or PC3 prostate cancer lines were maintained with appropriate media (ATCC recommended media + 10% FCS). Cells were harvested and resuspended at 0.6x10 6 cells/ml in media + 10% FCS. An aliquot of 45 ⁇ l of cells was added to each well of a 96-well microtiter plate. 5 ⁇ l of 100 ⁇ M vinblastine or 5 ⁇ l of 50 ⁇ M staurosporine or 5 ⁇ l of DMSO (solvent control) in RPMI media, was added to wells.
  • a quantitative method for determining an appropriate value for a minimum value for the ratio is to assess the control sample values and the standard deviation for the control sample: (Average Net RFU Control + 4x SD) / (Average Net RFU Control). This gives a statistically significant value to determine a cut-off value.
  • the mean and standard deviations of the inactive compounds can be used to determine an appropriate ratio. In these cases, the ratio for statistical significance ( ⁇ 0.01%) is greater than 7.5.
  • Examples 7 and 8 utilized solid tumor cells grown on a solid substratum then harvested and added directly to test sample. Assessed in this example was the effect on the level of caspase activation of harvesting cells, allowing time for adherence and then initiating treatment with test sample.
  • T47D and ZR 75-1 human breast cancer lines or PC3 prostate cancer lines maintained with appropriate media (ATCC recommended media + 10%) FCS) were used for evaluation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne une technique permettant d'identifier des composés antinéoplasiques thérapeutiquement efficaces, qui consiste à déterminer la capacité de composés testés à agir comme activateurs de la cascade de caspases dans des cellules de culture eucaryotes viables possédant une membrane cellulaire intacte, et exprimant le phénotype d'un cancer. Ladite technique permet de déterminer l'efficacité thérapeutique potentielle d'un composé testé qui renforce l'activité de la cascade de caspases est déterminé pour son. Cette technique différencie spécifiquement les activateurs de la cascade de caspases des poisons pour cellule non spécifiques. Une technique thérapeutique permettant de moduler l'apoptose in vivo ou une maladie néoplasique in vivo, consiste à administrer à un sujet une dose efficace d'un composé identifié comme étant activateur de la cascade de caspases. L'invention concerne aussi des composés, des compositions pharmaceutiques et un kit permettant de mettre en oeuvre ladite technique thérapeutique.
PCT/US2000/002329 1999-02-01 2000-02-01 Techniques d'identification d'agents antineoplasiques therapeutiquement efficaces avec des cellules de culture a membrane cellulaire intacte et produits correspondants WO2000045165A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00907081A EP1151295A4 (fr) 1999-02-01 2000-02-01 Techniques d'identification d'agents antineoplastiques therapeutiquement efficaces avec des cellules de culture a membrane cellulaire intacte et produits correspondant
AU28641/00A AU2864100A (en) 1999-02-01 2000-02-01 Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11810299P 1999-02-01 1999-02-01
US60/118,102 1999-02-01
US45459599A 1999-12-07 1999-12-07
US09/454,595 1999-12-07

Publications (1)

Publication Number Publication Date
WO2000045165A1 true WO2000045165A1 (fr) 2000-08-03

Family

ID=26815975

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/002329 WO2000045165A1 (fr) 1999-02-01 2000-02-01 Techniques d'identification d'agents antineoplasiques therapeutiquement efficaces avec des cellules de culture a membrane cellulaire intacte et produits correspondants

Country Status (3)

Country Link
EP (1) EP1151295A4 (fr)
AU (1) AU2864100A (fr)
WO (1) WO2000045165A1 (fr)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092085A1 (fr) * 2001-05-11 2002-11-21 Jung, Young-Hoon Compositions pharmaceutiques renfermant de la chelidonine ou des derives de la chelidonine
WO2003068946A1 (fr) * 2002-02-18 2003-08-21 Aventis Pharma Deutschland Gmbh Derives de phenalenone, leur procede de production et leur utilisation
US6759207B2 (en) 1997-10-10 2004-07-06 Cytovia, Inc. Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for caspases and other enzymes and the use thereof
US6828091B2 (en) 2000-08-03 2004-12-07 Cytovia, Inc. Method of identifying immunosuppressive agents
WO2004032876A3 (fr) * 2002-10-11 2005-03-31 Univ Texas Degueline utilisee comme agent de chimioprevention contre la cancer des poumons
WO2004002428A3 (fr) * 2002-07-01 2005-06-16 Cytovia Inc Derives d'acide de gomme-gutte et analogues utilises comme activateurs de caspases et inducteurs de l'apoptose
US6984718B2 (en) 1998-07-21 2006-01-10 Cytovia, Inc. Fluorescence dyes and their applications for whole-cell fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof
WO2006028969A1 (fr) * 2004-09-02 2006-03-16 Bionaut Pharmaceuticals, Inc. Traitement du cancer du pancreas au moyen d'inhibiteurs d'aptase na+/k+
EP1655027A1 (fr) * 2004-11-04 2006-05-10 Biofrontera Pharmaceuticals GmbH Utilisation du 9-(N-methyl-piperidyliden-4)-thioxanthene pour le traitement de l'hypertension pulmonaire et la migraine
WO2006029018A3 (fr) * 2004-09-02 2006-05-11 Bionaut Pharmaceuticals Inc Traitement chimiotherapeutique combinatoire utilisant des inhibiteurs de na+/k+-atpase
US7253206B2 (en) 2002-02-18 2007-08-07 Sanofi-Aventis Deutschland Gmbh Phenalenone derivatives, processes for preparation and use thereof
EP1539248A4 (fr) * 2002-03-29 2007-12-26 Univ Maryland Inhibiteurs de l'interaction proteine-proteine s100-p53 et methode d'inhibition du cancer utilisant lesdits inhibiteurs
WO2008026300A1 (fr) * 2006-08-28 2008-03-06 Nihon University Agent thérapeutique dérivé de graines de neem pour les tumeurs malignes
EP1967192A1 (fr) * 2007-03-09 2008-09-10 Riken Dérivés de N-amidino pyrazinecarboxamide pour l'utilisation dans la prophylaxie ou le traitement de maladies neurodégénératives
WO2008058269A3 (fr) * 2006-11-09 2009-03-26 Foldrx Pharmaceuticals Inc Composés et méthodes permettant de moduler l'acheminement des protéines
JP2010523719A (ja) * 2007-04-13 2010-07-15 サザン リサーチ インスティテュート 血管新生阻害薬及び使用方法
CN101869574A (zh) * 2010-07-24 2010-10-27 南京大学 哇巴因在增强非小细胞肺癌细胞敏感性中的应用
US20120128684A1 (en) * 2008-08-25 2012-05-24 Burnham Institute For Medical Research Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
CN102675273A (zh) * 2012-05-03 2012-09-19 吉林大学 3-芳基-8-烯丙基-7-羟基（甲氧基）香豆素及在制备抗肿瘤药物中的应用
JP2014517025A (ja) * 2011-06-15 2014-07-17 ライフ・アンド・ブレイン・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング グリア芽腫阻害化合物およびその使用
CN107219201A (zh) * 2017-04-20 2017-09-29 浙江工商大学 利用荧光显微镜观察桔霉素免疫后牛蛙抗体和亲和的方法
CN107602445A (zh) * 2016-07-12 2018-01-19 中国科学院上海药物研究所 咯哌丁胺衍生物及其在制备治疗混合谱系白血病的药物中的应用
US9974766B2 (en) * 2015-11-26 2018-05-22 Macau University Of Science And Technology Prenylated isoflavones for treatment of subjects with multidrug-resistant cancer
CN108096246A (zh) * 2017-03-08 2018-06-01 中国农业科学院饲料研究所 槲皮素和乌头碱联合用于制备治疗宫颈癌药物的应用及治疗宫颈癌药物
EP3312273A4 (fr) * 2015-06-19 2019-07-03 Tokyo University of Science Foundation Étiquette induisant la dégradation des protéines et son utilisation
CN111317734A (zh) * 2020-03-27 2020-06-23 广州医科大学附属第二医院 Wnt信号通路抑制剂和应用
CN112516134A (zh) * 2019-09-18 2021-03-19 上海医药集团股份有限公司 一种含羟基的化合物在制备药物中的应用
CN112545979A (zh) * 2021-01-12 2021-03-26 山西省肿瘤研究所 预防膀胱癌术后复发的灌注凝胶及其制备方法和应用
WO2021067799A1 (fr) * 2019-10-02 2021-04-08 The General Hospital Corporation Méthodes et substances de modulation de la voie nrf2
US11007269B2 (en) 2016-11-15 2021-05-18 Tokyo University Of Science Foundation P53 degradation inducing molecule and pharmaceutical composition
US11052154B2 (en) 2016-11-15 2021-07-06 Tokyo University Of Science Foundation Ras protein degradation inducing molecule and pharmaceutical composition
CN113559110A (zh) * 2021-08-27 2021-10-29 上海市第一人民医院 毒毛花苷在制备Nrf2抑制剂、与Nrf2异常活化有关疾病的药物中的应用
CN116270580A (zh) * 2023-01-31 2023-06-23 复旦大学 巴氯芬促进三阴性乳腺癌的免疫治疗用途
EP4045508A4 (fr) * 2019-10-17 2024-01-24 Chengdu Anticancer Bioscience, Ltd. Alcaloïdes de benzophénanthridine et leurs procédés d'utilisation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102600091B1 (ko) * 2016-08-24 2023-11-09 (주)아모레퍼시픽 사이토칼라신 d를 포함하는 피부 미백용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821072A (en) * 1996-02-20 1998-10-13 Sloan-Kettering Institute For Cancer Research Combinations of PKC inhibitors and therapaeutic agents for treating cancers
JP4068666B2 (ja) * 1997-05-22 2008-03-26 ザ バーナム インスティチュート カスパーゼ活性のアポトーシスインヒビター（ｉａｐ）タンパク質調節を変える薬剤についてのスクリーニングアッセイ
US6270980B1 (en) * 1997-06-05 2001-08-07 Idun Pharmaceuticals, Inc. Rapid methods for identifying modifiers of cellular apoptosis activity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FULDA ET AL.: "Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors", CANCER RESEARCH, vol. 57, 1 November 1997 (1997-11-01), pages 4956 - 4964, XP002927362 *
MOHR ET AL.: "Macrophages resistant to endogenously generated nitric oxide-mediated apoptosis are hypersensitive to exogenously added nitric oxide donors: Dichotomous apoptotic response independent of caspase 3 and reversal by the mitogen-activated protein kinase kinase (MEK) inhibitor PD 098059", PROC. NATL. ACAD. SCI. USA, vol. 95, April 1998 (1998-04-01), pages 5045 - 5050, XP002927361 *
QI ET AL.: "Baculovirus p35 and Z-VAD-fmk inhibit thapsigargin-induced apoptosis of breast cancer cells", ONCOGENE, vol. 15, 1997, pages 1207 - 1212, XP002927363 *
See also references of EP1151295A4 *

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759207B2 (en) 1997-10-10 2004-07-06 Cytovia, Inc. Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for caspases and other enzymes and the use thereof
US7270801B2 (en) 1997-10-10 2007-09-18 Cytovia, Inc. Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for caspases and other enzymes and the use thereof
US6984718B2 (en) 1998-07-21 2006-01-10 Cytovia, Inc. Fluorescence dyes and their applications for whole-cell fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof
US6828091B2 (en) 2000-08-03 2004-12-07 Cytovia, Inc. Method of identifying immunosuppressive agents
WO2002092085A1 (fr) * 2001-05-11 2002-11-21 Jung, Young-Hoon Compositions pharmaceutiques renfermant de la chelidonine ou des derives de la chelidonine
US7253206B2 (en) 2002-02-18 2007-08-07 Sanofi-Aventis Deutschland Gmbh Phenalenone derivatives, processes for preparation and use thereof
WO2003068946A1 (fr) * 2002-02-18 2003-08-21 Aventis Pharma Deutschland Gmbh Derives de phenalenone, leur procede de production et leur utilisation
US8053477B2 (en) 2002-03-29 2011-11-08 University Of Maryland, Baltimore Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same
EP1539248A4 (fr) * 2002-03-29 2007-12-26 Univ Maryland Inhibiteurs de l'interaction proteine-proteine s100-p53 et methode d'inhibition du cancer utilisant lesdits inhibiteurs
JP2006507227A (ja) * 2002-07-01 2006-03-02 サイトビア インコーポレイティッド カスパーゼ活性化剤およびアポトーシス誘導剤としてのガンボジック酸誘導体および類似体
US7176234B2 (en) 2002-07-01 2007-02-13 Cytovia, Inc. Derivatives of gambogic acid and analogs as activators of caspases and inducers of apoptosis
WO2004002428A3 (fr) * 2002-07-01 2005-06-16 Cytovia Inc Derives d'acide de gomme-gutte et analogues utilises comme activateurs de caspases et inducteurs de l'apoptose
WO2004032876A3 (fr) * 2002-10-11 2005-03-31 Univ Texas Degueline utilisee comme agent de chimioprevention contre la cancer des poumons
WO2006028969A1 (fr) * 2004-09-02 2006-03-16 Bionaut Pharmaceuticals, Inc. Traitement du cancer du pancreas au moyen d'inhibiteurs d'aptase na+/k+
WO2006029018A3 (fr) * 2004-09-02 2006-05-11 Bionaut Pharmaceuticals Inc Traitement chimiotherapeutique combinatoire utilisant des inhibiteurs de na+/k+-atpase
EP1655027A1 (fr) * 2004-11-04 2006-05-10 Biofrontera Pharmaceuticals GmbH Utilisation du 9-(N-methyl-piperidyliden-4)-thioxanthene pour le traitement de l'hypertension pulmonaire et la migraine
WO2008026300A1 (fr) * 2006-08-28 2008-03-06 Nihon University Agent thérapeutique dérivé de graines de neem pour les tumeurs malignes
WO2008058269A3 (fr) * 2006-11-09 2009-03-26 Foldrx Pharmaceuticals Inc Composés et méthodes permettant de moduler l'acheminement des protéines
EP1967192A1 (fr) * 2007-03-09 2008-09-10 Riken Dérivés de N-amidino pyrazinecarboxamide pour l'utilisation dans la prophylaxie ou le traitement de maladies neurodégénératives
CN101801386A (zh) * 2007-04-13 2010-08-11 南方研究所 抗血管生成剂和使用方法
KR101519028B1 (ko) * 2007-04-13 2015-05-11 써던 리서취 인스티튜트 항혈관형성제 및 사용방법
EP2139325A4 (fr) * 2007-04-13 2011-09-14 Southern Res Inst Agents anti-angiogéniques et procédés d'utilisation
JP2010523719A (ja) * 2007-04-13 2010-07-15 サザン リサーチ インスティテュート 血管新生阻害薬及び使用方法
AU2009238237B2 (en) * 2007-04-13 2013-02-07 Southern Research Institute Anti-Angiogenic Agents and Methods of Use
AU2008287285B2 (en) * 2007-04-13 2013-05-16 Southern Research Institute Anti-angiogenic agents and methods of use
US8367737B2 (en) 2007-04-13 2013-02-05 Southern Research Institute Method of using biothionol and biothionol-like compounds as anti-angiogenic agents
US20120128684A1 (en) * 2008-08-25 2012-05-24 Burnham Institute For Medical Research Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
CN101869574B (zh) * 2010-07-24 2011-12-21 南京大学 哇巴因在增强非小细胞肺癌细胞敏感性中的应用
CN101869574A (zh) * 2010-07-24 2010-10-27 南京大学 哇巴因在增强非小细胞肺癌细胞敏感性中的应用
JP2014517025A (ja) * 2011-06-15 2014-07-17 ライフ・アンド・ブレイン・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング グリア芽腫阻害化合物およびその使用
CN102675273A (zh) * 2012-05-03 2012-09-19 吉林大学 3-芳基-8-烯丙基-7-羟基（甲氧基）香豆素及在制备抗肿瘤药物中的应用
US10976306B2 (en) 2015-06-19 2021-04-13 Tokyo University Of Science Foundation Protein degradation inducing tag and usage thereof
AU2016279493B2 (en) * 2015-06-19 2022-08-11 Etsuko Miyamoto Protein degradation inducing tag and usage thereof
EP3868878A3 (fr) * 2015-06-19 2022-01-05 Tokyo University of Science Foundation Étiquette d'induction de la dégradation de protéines et son utilisation
EP3312273A4 (fr) * 2015-06-19 2019-07-03 Tokyo University of Science Foundation Étiquette induisant la dégradation des protéines et son utilisation
US9974766B2 (en) * 2015-11-26 2018-05-22 Macau University Of Science And Technology Prenylated isoflavones for treatment of subjects with multidrug-resistant cancer
CN107602445A (zh) * 2016-07-12 2018-01-19 中国科学院上海药物研究所 咯哌丁胺衍生物及其在制备治疗混合谱系白血病的药物中的应用
US11052154B2 (en) 2016-11-15 2021-07-06 Tokyo University Of Science Foundation Ras protein degradation inducing molecule and pharmaceutical composition
US11007269B2 (en) 2016-11-15 2021-05-18 Tokyo University Of Science Foundation P53 degradation inducing molecule and pharmaceutical composition
CN108096246A (zh) * 2017-03-08 2018-06-01 中国农业科学院饲料研究所 槲皮素和乌头碱联合用于制备治疗宫颈癌药物的应用及治疗宫颈癌药物
CN107219201B (zh) * 2017-04-20 2019-11-12 浙江工商大学 利用荧光显微镜观察桔霉素免疫后牛蛙抗体和亲和的方法
CN107219201A (zh) * 2017-04-20 2017-09-29 浙江工商大学 利用荧光显微镜观察桔霉素免疫后牛蛙抗体和亲和的方法
CN112516134A (zh) * 2019-09-18 2021-03-19 上海医药集团股份有限公司 一种含羟基的化合物在制备药物中的应用
CN112516134B (zh) * 2019-09-18 2023-06-06 上海医药集团股份有限公司 一种含羟基的化合物在制备药物中的应用
WO2021067799A1 (fr) * 2019-10-02 2021-04-08 The General Hospital Corporation Méthodes et substances de modulation de la voie nrf2
EP4045508A4 (fr) * 2019-10-17 2024-01-24 Chengdu Anticancer Bioscience, Ltd. Alcaloïdes de benzophénanthridine et leurs procédés d'utilisation
CN111317734A (zh) * 2020-03-27 2020-06-23 广州医科大学附属第二医院 Wnt信号通路抑制剂和应用
CN112545979A (zh) * 2021-01-12 2021-03-26 山西省肿瘤研究所 预防膀胱癌术后复发的灌注凝胶及其制备方法和应用
CN113559110A (zh) * 2021-08-27 2021-10-29 上海市第一人民医院 毒毛花苷在制备Nrf2抑制剂、与Nrf2异常活化有关疾病的药物中的应用
CN116270580A (zh) * 2023-01-31 2023-06-23 复旦大学 巴氯芬促进三阴性乳腺癌的免疫治疗用途

Also Published As

Publication number Publication date
EP1151295A4 (fr) 2005-03-30
EP1151295A1 (fr) 2001-11-07
AU2864100A (en) 2000-08-18

Similar Documents

Publication Publication Date Title
WO2000045165A1 (fr) Techniques d'identification d'agents antineoplasiques therapeutiquement efficaces avec des cellules de culture a membrane cellulaire intacte et produits correspondants
Lin et al. Involvement of Bcl-2 family, cytochrome c and caspase 3 in induction of apoptosis by beauvericin in human non-small cell lung cancer cells
Genini et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria
Roy et al. Mitochondria-dependent reactive oxygen species-mediated programmed cell death induced by 3, 3′-diindolylmethane through inhibition of F0F1-ATP synthase in unicellular protozoan parasite Leishmania donovani
Ding et al. The alkaloid sanguinarine is effective against multidrug resistance in human cervical cells via bimodal cell death
King et al. Respiratory enzymes and mitochondrial morphology of HeLa and L cells treated with chloramphenicol and ethidium bromide
Mullally et al. Pharmacophore model for novel inhibitors of ubiquitin isopeptidases that induce p53-independent cell death
Čáňová et al. Flubendazole induces mitotic catastrophe and apoptosis in melanoma cells
Finiuk et al. Proapoptotic effects of novel thiazole derivative on human glioma cells
Yang et al. Up-regulation of Bax and endonuclease G, and down-modulation of Bcl-XL involved in cardiotoxin III-induced apoptosis in K562 cells
US11197844B2 (en) Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer
JP2012504646A (ja) 選択的サイクリン依存性キナーゼ４／６阻害剤を用いた化学療法化合物に対する造血系の防護
Lynch et al. Targets and mechanisms of chemically induced aneuploidy. Part 1 of the report of the 2017 IWGT workgroup on assessing the risk of aneugens for carcinogenesis and hereditary diseases
Misiewicz et al. Sulforaphane-mediated induction of a phase 2 detoxifying enzyme NAD (P) H: quinone reductase and apoptosis in human lymphoblastoid cells.
Velentzas et al. Detrimental effects of proteasome inhibition activity in Drosophila melanogaster: implication of ER stress, autophagy, and apoptosis
KR20220061190A (ko) Atp-기반 세포 분류 및 과증식성 암 줄기 세포
Jimenez et al. Chloramphenicol-induced bone marrow injury: possible role of bacterial metabolites of chloramphenicol
Bouwer et al. NMS-873 functions as a dual inhibitor of mitochondrial oxidative phosphorylation
US5324720A (en) Methods of achieving antitumor activity using 16-membered-macrolide-type compounds
US20030027229A1 (en) Methods of identifying potentially therapeutically selective and effective anti-cancer agents that are inducers of apoptosis
Aguiló et al. Granzyme B of cytotoxic T cells induces extramitochondrial reactive oxygen species production via caspase‐dependent NADPH oxidase activation
US5306716A (en) Methods of achieving antileukemia activity using 16-membered-macrolide-type compounds
Baggetto et al. In vitro and in vivo reversal of cancer cell multidrug resistance by the semi-synthetic antibiotic tiamulin
KR20050083631A (ko) 항암 약물을 위한 스크리닝 스트래티지
Dexheimer et al. Combination screen in multi-cell type tumor spheroids reveals interaction between aryl hydrocarbon receptor antagonists and E1 ubiquitin-activating enzyme inhibitor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000907081

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000907081

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000907081

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载